» Articles » PMID: 35309213

Emergence of Hypervirulent ST11-K64 Poses a Serious Clinical Threat in Older Patients

Overview
Specialty Public Health
Date 2022 Mar 21
PMID 35309213
Authors
Affiliations
Soon will be listed here.
Abstract

The carbapenem-resistant hypervirulent (CR-hvKP) poses a severe therapeutic challenge to global public health, and research on CR-hvKP in older patients remain limited. In this study, we aimed to investigate the clinical and molecular characteristics and risk factors of CR-hvKP infections in older patients. We retrospectively investigated older patients with carbapenem-resistant (CRKP) infections in the intensive care unit (ICU) between January 2020 and December 2020. The clinical data, and microbiological data including antimicrobial susceptibility testing, phenotype experiment and detection of carbapenemases, string test, virulence genes, capsular serotype-specific (cps) genes, and multilocus sequence typing, of the CR-hvKP group defined by the presence of any one of the virulence genes, including , and were compared with those of CR-non-hvKP strains. Of the 80 CRKP strains, 51 (63.8%) met the definition of CR-hvKP. The main mechanism of resistance to carbapenems was the presence of the gene. Sequence type (ST)11 (81.3%, 65/80) and ST15 (16.3%, 13/80) were the most common STs in CRKP strains. The minimum inhibitory concentration (MIC) values of the CR-hvKP group against the six tested antibiotics (ceftazidime, ceftazidime-avibactam, imipenem-avibactam, tigecycline, levofloxacin, and Cefoperazone-Sulbactam) exhibited elevated levels than the CR-non-hvKP group. Ceftazidime and imipenem by combining avibactam (4 μg/mL) significantly decreased the MIC values more than 16-fold than ceftazidime and imipenem alone against carbapenemase (KPC)-2-producing . Cardiovascular disease [odds ratio (OR) = 11.956] and ST11-K64 (OR = 8.385) appeared to be independent variables associated with CR-hvKP infection by multivariate analysis. In conclusion, higher MICs of the last line antibiotic agents (ceftazidime-avibactam, tigecycline) might be a critical consideration in the clinical management of older patients where the concentration of these toxic antibiotics matters because of underlying comorbidities. Caution regarding KPC-2-producing ST11-K64 CR-hvKP as being new significant "superbugs" is required as they are widespread, and infection control measures should be strengthened to curb further dissemination in nosocomial settings in China.

Citing Articles

Systematic review and meta-analysis on the carbapenem-resistant hypervirulent Klebsiella pneumoniae isolates.

Qala Nou M, Amirian Z, Dehghani F, Vejdan A, Rooin R, Dehghanmehr S BMC Pharmacol Toxicol. 2025; 26(1):25.

PMID: 39885589 PMC: 11783860. DOI: 10.1186/s40360-025-00857-8.


Molecular Characterization and Risk Factors of Carbapenem-Resistant Hypervirulent Isolated from Chinese Tertiary Hospital.

Zhu R, Li J, Lian S, Li Y, Cai M, Cao Y Infect Drug Resist. 2025; 18:83-92.

PMID: 39803307 PMC: 11720998. DOI: 10.2147/IDR.S494208.


Emergence and clinical challenges of ST11-K64 carbapenem-resistant Klebsiella pneumoniae: molecular insights and implications for antimicrobial resistance and virulence in Southwest China.

Li L, Liang J, Zhang H, Guo J, Li S, Li M BMC Infect Dis. 2025; 25(1):19.

PMID: 39754049 PMC: 11699810. DOI: 10.1186/s12879-024-10390-4.


Phenotypic and genomic characterization of ST11-K1 CR-hvKP with highly homologous -bearing plasmids in China.

Han Y, Wang H, Zhu H, Lv Y, Zhao W, Wang Y mSystems. 2024; 9(12):e0110124.

PMID: 39555910 PMC: 11651102. DOI: 10.1128/msystems.01101-24.


Predictors of Mortality, Drug Resistance, and Determinants among Carbapenem-Resistant Infections in Chinese Elderly Patients.

Zhang Y, Zou C, Qin J, Li M, Wang X, Wei T Can J Infect Dis Med Microbiol. 2024; 2024:5459549.

PMID: 39234528 PMC: 11374419. DOI: 10.1155/2024/5459549.


References
1.
Zheng X, Wang J, Xu W, Xu J, Hu J . Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant bloodstream infections in the intensive care unit. Antimicrob Resist Infect Control. 2017; 6:102. PMC: 5625719. DOI: 10.1186/s13756-017-0256-2. View

2.
Nadasy K, Domiati-Saad R, Tribble M . Invasive Klebsiella pneumoniae syndrome in North America. Clin Infect Dis. 2007; 45(3):e25-8. DOI: 10.1086/519424. View

3.
Jiao Y, Qin Y, Liu J, Li Q, Dong Y, Shang Y . Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathog Glob Health. 2015; 109(2):68-74. PMC: 4455340. DOI: 10.1179/2047773215Y.0000000004. View

4.
Liao W, Liu Y, Zhang W . Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: A review over the last 10 years. J Glob Antimicrob Resist. 2020; 23:174-180. DOI: 10.1016/j.jgar.2020.09.004. View

5.
Lee C, Lee J, Park K, Jeon J, Kim Y, Cha C . Antimicrobial Resistance of Hypervirulent : Epidemiology, Hypervirulence-Associated Determinants, and Resistance Mechanisms. Front Cell Infect Microbiol. 2017; 7:483. PMC: 5702448. DOI: 10.3389/fcimb.2017.00483. View